Leading Companies

Novaremed AG

Novaremed is a clinical-stage Swiss biopharmaceutical company focused on the development of NRD.E1, an orally active New Chemical Entity (NCE) for the treatment of Neuropathic Pain. After the relocation to Basel in 2018, Novaremed is currently preparing for a global Phase IIb study in DNP.

Novaremed AG

Teichgässlein 9
4058 Basel

Bio Technology (Biotech)
Life Science
Country of Origin
Recommend us

Premium Partner

Strategic partners

Institutional partner

Official program